CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 39

CardioVascular BioTherapeutics, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - H2 2011” provides data on the CardioVascular BioTherapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CardioVascular BioTherapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from CardioVascular BioTherapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CardioVascular BioTherapeutics, Inc. - Brief CardioVascular BioTherapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CardioVascular BioTherapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CardioVascular BioTherapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CardioVascular BioTherapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CardioVascular BioTherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CardioVascular BioTherapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CardioVascular BioTherapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CardioVascular BioTherapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CardioVascular BioTherapeutics, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of CardioVascular BioTherapeutics, Inc.; CardioVascular BioTherapeutics, Inc. - Key Therapeutics; CardioVascular BioTherapeutics, Inc. - Pipeline Overview and Promising Molecules; CardioVascular BioTherapeutics, Inc. - News; CardioVascular BioTherapeutics, Inc. - Latest Updates; CardioVascular BioTherapeutics, Inc. - Pipeline; CardioVascular BioTherapeutics, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
CardioVascular BioTherapeutics, Inc. Snapshot
CardioVascular BioTherapeutics, Inc. Overview
Key Information
Key Facts
CardioVascular BioTherapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
CardioVascular BioTherapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CardioVascular BioTherapeutics, Inc. – Pipeline Products Glance
CardioVascular BioTherapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CardioVascular BioTherapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
CardioVascular BioTherapeutics, Inc. – Drug Profiles
CVBT-141C
Product Description
Mechanism of Action
R&D Progress
CVBT-141G
Product Description
Mechanism of Action
R&D Progress
FGF-1141
Product Description
Mechanism of Action
R&D Progress
CardioVascular BioTherapeutics, Inc. – Pipeline Analysis
CardioVascular BioTherapeutics, Inc. – Pipeline Products by Therapeutic Class
CardioVascular BioTherapeutics, Inc. - Pipeline Products By Target
CardioVascular BioTherapeutics, Inc. – Pipeline Products by Route of Administration
CardioVascular BioTherapeutics, Inc. – Pipeline Products by Molecule Type
CardioVascular BioTherapeutics, Inc. – Recent Pipeline Updates
CardioVascular BioTherapeutics, Inc. - Dormant Projects
CardioVascular BioTherapeutics, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 25, 2008: CardioVascular BioTherapeutics Initiates Phase II Clinical Trial Of CVBT-141H For Severe Coronary Heart Disease
Nov 25, 2008: CVBT Doses First Patient In Its Phase II Clinical Trial For Severe Coronary Heart Disease
Jul 12, 2007: CardioVascular BioTherapeutics Announces Preclinical Study Results
Jan 04, 2011: CardioVascular BioTherapeutics Announces Diabetic Wounds Drug Phase II Trial Data
Feb 03, 2011: CardioVascular BioTherapeutics Submits FDA Application For 'Fast Track' Status For CVBT-141B
Oct 02, 2007: CardioVascular BioTherapeutics Completes Phase I Trial Of CVBT-141B For Diabetic
Financial Deals Landscape
CardioVascular BioTherapeutics, Inc., Deals Summary
CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
CardioVascular BioTherapeutics Enters Into Co-Development Agreement With Cardio Neo-Genesis
Cardiovascular Biotherapeutics Forms Partnership With Phillip Frey Jr.
Licensing Agreements
Cardiovascular BioTherapeutics Enters Into Licensing Agreement With An Affiliate Of Merck
Equity Offering
CardioVascular BioTherapeutics Completes Private Placement Of $15 Million
CardioVascular BioTherapeutics Completes Initial Public Offering Of $17 Million
Debt Offering
CardioVascular BioTherapeutics Completes Private Placement Of Senior Secured notes For $20 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
CardioVascular BioTherapeutics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
CardioVascular BioTherapeutics, Inc. – Pipeline by Stage of Development, H2 2011
CardioVascular BioTherapeutics, Inc. – Monotherapy Products in Pipeline, H2 2011
CardioVascular BioTherapeutics, Inc. - Phase II, H2 2011
CardioVascular BioTherapeutics, Inc. - Phase I, H2 2011
CardioVascular BioTherapeutics, Inc. - Pipeline By Therapeutic Class, H2 2011
CardioVascular BioTherapeutics, Inc. - Pipeline By Target, H2 2011
CardioVascular BioTherapeutics, Inc. – Pipeline By Route of Administration, H2 2011
CardioVascular BioTherapeutics, Inc. – Pipeline By Molecule Type, H2 2011
CardioVascular BioTherapeutics, Inc. – Recent Pipeline Updates, H2 2011
CardioVascular BioTherapeutics, Inc. - Dormant Developmental Projects, 2010
CardioVascular BioTherapeutics, Inc., Other Locations
CardioVascular BioTherapeutics, Inc., Deals Summary
CardioVascular BioTherapeutics Enters Into Co-Development Agreement With Cardio Neo-Genesis
Cardiovascular Biotherapeutics Forms Partnership With Phillip Frey Jr.
Cardiovascular BioTherapeutics Enters Into Licensing Agreement With An Affiliate Of Merck
CardioVascular BioTherapeutics Completes Private Placement Of $15 Million
CardioVascular BioTherapeutics Completes Initial Public Offering Of $17 Million
CardioVascular BioTherapeutics Completes Private Placement Of Senior Secured notes For $20 Million

List of Figures
CardioVascular BioTherapeutics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
CardioVascular BioTherapeutics, Inc. – Pipeline by Stage of Development, H2 2011
CardioVascular BioTherapeutics, Inc. – Monotherapy Products in Pipeline, H2 2011
CardioVascular BioTherapeutics, Inc. – Pipeline By Therapeutic Class, H2 2011
CardioVascular BioTherapeutics, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Abbott Laboratories - IT Sales Opportunities - 2009
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model